Abstract：
BACKGROUND: Lokivetmab, a caninised monoclonal antibody against interleukin (IL)-31, is an effective treatment for the pruritus associated with canine atopic dermatitis (cAD).
OBJECTIVE: To investigate the efficacy and safety of lokivetmab during long-term treatment defined as at least three consecutive lokivetmab injections in atopic dogs under field conditions. To assess individual factors influencing treatment outcome and adverse events.
METHODS: 150 dogs with cAD.
METHODS: Medical records of dogs treated with lokivetmab were reviewed, and owners and/or veterinarians were contacted as needed for follow-up. A decrease of the pruritus Visual Analog Scale (PVAS) score by ≥2 or a PVAS score ≤2 after treatment was considered as treatment success. Logistic regression was used to investigate the influence of a variety of factors on outcome: type of cAD (food versus environment), age at first lokivetmab administration, disease chronicity, dosage and/or secondary infection. Any adverse event that occurred during the study period was recorded.
RESULTS: Lokivetmab reduced the PVAS score with long-term use (p < 0.01); the success rate was 53 of 69 total dogs (77%). The probability of treatment failure decreased with increasing treatment duration. None of the factors investigated influenced the treatment outcome. Twelve dogs of 150 (8%) showed adverse events such as gastrointestinal signs or lethargy.
CONCLUSIONS: Lokivetmab appears to be an effective and safe long-term anti-itch therapy for dogs with cAD.
OBJECTIVE: To investigate the efficacy and safety of lokivetmab during long-term treatment defined as at least three consecutive lokivetmab injections in atopic dogs under field conditions. To assess individual factors influencing treatment outcome and adverse events.
METHODS: 150 dogs with cAD.
METHODS: Medical records of dogs treated with lokivetmab were reviewed, and owners and/or veterinarians were contacted as needed for follow-up. A decrease of the pruritus Visual Analog Scale (PVAS) score by ≥2 or a PVAS score ≤2 after treatment was considered as treatment success. Logistic regression was used to investigate the influence of a variety of factors on outcome: type of cAD (food versus environment), age at first lokivetmab administration, disease chronicity, dosage and/or secondary infection. Any adverse event that occurred during the study period was recorded.
RESULTS: Lokivetmab reduced the PVAS score with long-term use (p < 0.01); the success rate was 53 of 69 total dogs (77%). The probability of treatment failure decreased with increasing treatment duration. None of the factors investigated influenced the treatment outcome. Twelve dogs of 150 (8%) showed adverse events such as gastrointestinal signs or lethargy.
CONCLUSIONS: Lokivetmab appears to be an effective and safe long-term anti-itch therapy for dogs with cAD.
摘要：
背景：Lokivetmab，抗白细胞介素（IL）-31的犬化单克隆抗体是与犬特应性皮炎（cAD）相关的瘙痒的有效治疗方法。
目的：研究lokivetmab在野外条件下至少连续三次注射lokivetmab的长期治疗中的疗效和安全性。评估影响治疗结果和不良事件的个体因素。
方法：150只cAD犬。
方法：回顾了用lokivetmab治疗的狗的病历，并根据需要联系业主和/或兽医进行随访。治疗后瘙痒视觉模拟量表（PVAS）评分降低≥2或PVAS评分≤2被认为是治疗成功。使用Logistic回归来调查多种因素对结果的影响：cAD类型（食物与环境），Lokivetmab最初管理的年龄，疾病慢性，剂量和/或继发感染。记录研究期间发生的任何不良事件。
结果：Lokivetmab长期使用可降低PVAS评分（p<0.01）；成功率为69只狗中的53只（77％）。治疗失败的可能性随着治疗持续时间的增加而降低。研究的因素均不影响治疗结果。150只狗中的12只（8％）显示出不良事件，例如胃肠道体征或嗜睡。
结论：Lokivetmab对cAD犬似乎是一种有效且安全的长期抗痒疗法。
目的：研究lokivetmab在野外条件下至少连续三次注射lokivetmab的长期治疗中的疗效和安全性。评估影响治疗结果和不良事件的个体因素。
方法：150只cAD犬。
方法：回顾了用lokivetmab治疗的狗的病历，并根据需要联系业主和/或兽医进行随访。治疗后瘙痒视觉模拟量表（PVAS）评分降低≥2或PVAS评分≤2被认为是治疗成功。使用Logistic回归来调查多种因素对结果的影响：cAD类型（食物与环境），Lokivetmab最初管理的年龄，疾病慢性，剂量和/或继发感染。记录研究期间发生的任何不良事件。
结果：Lokivetmab长期使用可降低PVAS评分（p<0.01）；成功率为69只狗中的53只（77％）。治疗失败的可能性随着治疗持续时间的增加而降低。研究的因素均不影响治疗结果。150只狗中的12只（8％）显示出不良事件，例如胃肠道体征或嗜睡。
结论：Lokivetmab对cAD犬似乎是一种有效且安全的长期抗痒疗法。
